CompletedPhase 1NCT03955042

Pemetrexed for the Treatment of Chordoma

Studying Chordoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Saint John's Cancer Institute
Principal Investigator
Santosh Kesari, MD, PhD
Saint John's Cancer Institute
Intervention
Pemetrexed(drug)
Enrollment
15 enrolled
Eligibility
18 years · All sexes
Timeline
20192023

Study locations (1)

Collaborators

Eli Lilly and Company · Chordoma Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03955042 on ClinicalTrials.gov

Other trials for Chordoma

Additional recruiting or active studies for the same condition.

See all trials for Chordoma

← Back to all trials